Special Issue

Development of Antimicrobial Biomaterials and Natural Alternatives against Biofilms and Implant-Related Infections

Message from the Guest Editors

Implant infection is one of the most frequent and severe complications associated with the use of biomaterials. Implant infections count as nosocomial infections, being a major cause of death and increased morbidity among hospitalized patients. The presence of biofilm results in antibiotic tolerance by bacteria because many of them cannot sufficiently penetrate through biofilms. There is an urgent need to investigate alternatives to antibiotic substances. This Special Issue seeks manuscript submissions that further investigate such substances in association with biomaterials for use in all areas of implantology. Submissions on local delivery systems, smart implants associated with antibiotic boosting substances, natural antimicrobials, and new antimicrobial substances are especially encouraged. Keywords: Biofilms; Implant infections; Antimicrobials; Biomedical engineering; Biomaterials; Polymers; Local delivery systems; Dental medicine; Bone cements; **Endodontics**

Guest Editors

Prof. Dr. Débora C. Coraça-Huber

Prof. Dr. Eliana Aparecida de Rezende Duek

Prof. Dr. Marina Angélica Marciano da Silva

Deadline for manuscript submissions

closed (15 September 2021)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/68913

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

